Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis

被引:144
作者
Bal, A.
Unlu, E.
Bahar, G.
Aydog, E.
Eksioglu, E.
Yorgancioglu, R.
机构
[1] Ankara Diskapi Educ & Res Hosp, Dept PMR, Hlth Minist, Ankara, Turkey
[2] Ankara Diskapi Educ & Res Hosp, Dept Microbiol, Hlth Minist, Ankara, Turkey
关键词
ankylosing spondylitis; IL-1; beta; IL-6; sIL-2R; TNF-alpha;
D O I
10.1007/s10067-006-0283-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatological disease affecting primarily the sacroiliac joint and vertebral column, with an etiology that remains obscure. Cytokines are soluble proteins that have specific roles in inflammatory response, arranging the interaction between cells of the immune system both in natural and specific immune reactions. This study was planned to evaluate the relation between the level of cytokines and the clinical and laboratory findings of patients with AS compared to healthy subjects. In this study, we demonstrated increased serum levels of soluble interleukin-2 receptor (sIL-2R), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in patients with AS compared with healthy subjects. Only IL-1 beta levels were not increased in AS patients. We found a correlation between C-reactive protein and IL-6 levels and between erythrocyte sedimentation rate and sIL-2R, IL-6 and TNF-alpha levels. Only the sIL-2R level was correlated with Bath AS Metrology Index and Bath AS Functional Index. We suggest that sIL-2R, IL-6, and TNF-alpha may have a role in the pathogenesis of AS and that their serum levels can be used as disease activity parameters and tools for diagnosis.
引用
收藏
页码:211 / 215
页数:5
相关论文
共 23 条
[1]  
BANKS RE, 1998, OXFORD TXB RHEUMATOL, P623
[2]  
CAIN A, 1994, J RHEUMATOL, V21, P2281
[3]  
Claudepierre P, 1997, BRIT J RHEUMATOL, V36, P400
[4]  
DINARELLO C. A., 1999, PROINFLAMMATORY ANTI
[5]  
DINARELLO CA, 1989, TXB RHEUMATOLOGY, P285
[6]   In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility [J].
Falkenbach, A ;
Herold, M .
RHEUMATOLOGY INTERNATIONAL, 1998, 18 (03) :103-106
[7]  
GARRETT S, 1994, J RHEUMATOL, V21, P2286
[8]  
GOEITHE HS, 1985, BRIT J RHEUMATOL, V24, P242
[9]  
GRATACOS J, 1994, BRIT J RHEUMATOL, V33, P927
[10]   Open label trial of anakinra in active ankylosing spondylitis over 24 weeks [J].
Haibel, H ;
Rudwaleit, M ;
Listing, J ;
Sieper, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :296-298